DE2510926C3 - 4'-epi-Daunomycuie, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen - Google Patents
4'-epi-Daunomycuie, deren Herstellung und diese Verbindungen enthaltende pharmazeutische ZusammensetzungenInfo
- Publication number
- DE2510926C3 DE2510926C3 DE2510926A DE2510926A DE2510926C3 DE 2510926 C3 DE2510926 C3 DE 2510926C3 DE 2510926 A DE2510926 A DE 2510926A DE 2510926 A DE2510926 A DE 2510926A DE 2510926 C3 DE2510926 C3 DE 2510926C3
- Authority
- DE
- Germany
- Prior art keywords
- epi
- compounds
- daunomycuie
- preparation
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 title description 13
- 239000008194 pharmaceutical composition Substances 0.000 title description 2
- 238000002360 preparation method Methods 0.000 title description 2
- YOFDHOWPGULAQF-MQJDWESPSA-N (7s,9s)-9-acetyl-6,7,9,11-tetrahydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@@](O)(C(C)=O)C[C@H](O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-MQJDWESPSA-N 0.000 claims description 9
- YOFDHOWPGULAQF-UHFFFAOYSA-N Daunomycin-Aglycone Natural products C1C(O)(C(C)=O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O YOFDHOWPGULAQF-UHFFFAOYSA-N 0.000 claims description 9
- STQGQHZAVUOBTE-HQXHJQOISA-N (7s,9s)-9-acetyl-7-[(2r,4r,5s,6r)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@@H](N)[C@H](O)[C@@H](C)O1 STQGQHZAVUOBTE-HQXHJQOISA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 150000002402 hexoses Chemical class 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 238000003359 percent control normalization Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NGYIMTKLQULBOO-UHFFFAOYSA-L mercury dibromide Chemical compound Br[Hg]Br NGYIMTKLQULBOO-UHFFFAOYSA-L 0.000 description 2
- -1 mercury halide Chemical class 0.000 description 2
- 229910000474 mercury oxide Inorganic materials 0.000 description 2
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 2
- WPJRFCZKZXBUNI-ZLUOBGJFSA-N (3s,4r,5s)-3-amino-4,5-dihydroxyhexanal Chemical compound C[C@H](O)[C@H](O)[C@@H](N)CC=O WPJRFCZKZXBUNI-ZLUOBGJFSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 238000006994 Koenigs-Knorr glycosidation reaction Methods 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N hexopyranose Chemical compound OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1225474A GB1457559A (en) | 1974-03-20 | 1974-03-20 | Daunomycins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2510926A1 DE2510926A1 (de) | 1975-09-25 |
| DE2510926B2 DE2510926B2 (de) | 1979-07-19 |
| DE2510926C3 true DE2510926C3 (de) | 1980-03-13 |
Family
ID=10001195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2510926A Expired DE2510926C3 (de) | 1974-03-20 | 1975-03-13 | 4'-epi-Daunomycuie, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JPS5833880B2 (en, 2012) |
| AT (1) | AT338419B (en, 2012) |
| BE (1) | BE826848A (en, 2012) |
| CA (1) | CA1046508A (en, 2012) |
| CH (1) | CH615198A5 (en, 2012) |
| DE (1) | DE2510926C3 (en, 2012) |
| DK (1) | DK146541C (en, 2012) |
| FR (1) | FR2264554B1 (en, 2012) |
| GB (1) | GB1457559A (en, 2012) |
| NL (1) | NL176636C (en, 2012) |
| SE (1) | SE434843B (en, 2012) |
| SU (1) | SU589926A3 (en, 2012) |
| ZA (1) | ZA751687B (en, 2012) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124317A (en) | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.P.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5977082A (en) * | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| FR2678274A1 (fr) * | 1991-06-25 | 1992-12-31 | Medgenix Group Sa | N-leucyl epirubicine application a titre de medicament antitumoral et procede de preparation. |
-
1974
- 1974-03-20 GB GB1225474A patent/GB1457559A/en not_active Expired
-
1975
- 1975-03-13 DE DE2510926A patent/DE2510926C3/de not_active Expired
- 1975-03-14 NL NLAANVRAGE7503079,A patent/NL176636C/xx not_active IP Right Cessation
- 1975-03-17 AT AT202875A patent/AT338419B/de not_active IP Right Cessation
- 1975-03-18 SU SU752129602A patent/SU589926A3/ru active
- 1975-03-18 SE SE7503084A patent/SE434843B/xx not_active IP Right Cessation
- 1975-03-18 ZA ZA00751687A patent/ZA751687B/xx unknown
- 1975-03-18 DK DK109275A patent/DK146541C/da not_active IP Right Cessation
- 1975-03-19 BE BE154470A patent/BE826848A/xx not_active IP Right Cessation
- 1975-03-19 JP JP50033493A patent/JPS5833880B2/ja not_active Expired
- 1975-03-19 FR FR7508547A patent/FR2264554B1/fr not_active Expired
- 1975-03-19 CH CH352975A patent/CH615198A5/de not_active IP Right Cessation
- 1975-03-20 CA CA222,610A patent/CA1046508A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| ZA751687B (en) | 1976-02-25 |
| JPS5833880B2 (ja) | 1983-07-22 |
| DK146541B (da) | 1983-10-31 |
| CA1046508A (en) | 1979-01-16 |
| ATA202875A (de) | 1976-12-15 |
| NL7503079A (nl) | 1975-09-23 |
| DE2510926A1 (de) | 1975-09-25 |
| FR2264554B1 (en, 2012) | 1978-07-28 |
| FR2264554A1 (en, 2012) | 1975-10-17 |
| GB1457559A (en) | 1976-12-08 |
| SU589926A3 (ru) | 1978-01-25 |
| NL176636C (nl) | 1985-05-17 |
| BE826848A (fr) | 1975-09-19 |
| DK109275A (en, 2012) | 1975-09-21 |
| CH615198A5 (en) | 1980-01-15 |
| SE7503084L (en, 2012) | 1975-09-22 |
| NL176636B (nl) | 1984-12-17 |
| AT338419B (de) | 1977-08-25 |
| AU7919775A (en) | 1976-09-23 |
| JPS50126657A (en, 2012) | 1975-10-04 |
| SE434843B (sv) | 1984-08-20 |
| DK146541C (da) | 1984-04-09 |
| DE2510926B2 (de) | 1979-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2510866C3 (de) | 4'-epi-Adriamycin a - und ß -Anomer, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE2525633C3 (en, 2012) | ||
| DE2618822C3 (de) | Anthracyclin-Glycoside und Verfahren zu deren Herstellung | |
| DE69710573T2 (de) | Morpholinyl-anthracyclinderivate | |
| DE3214559C2 (de) | 4'-Desoxy-4'-iod-daunorubicin und -doxorubicin und diese Verbindungen enthaltende Arzneimittel | |
| DE2530416A1 (de) | Alkylaminoglucopyranosid-derivate und verfahren zu ihrer herstellung | |
| DE69312729T2 (de) | Antiproliferative und entzündungshemmende verbindungen. pentose monosaccharid-derivate | |
| DE60005300T2 (de) | 2,3-o-isoproylidene derivativen von monosacchariden und verwendung als zell-adhäsion-inhibitoren | |
| DE2510926C3 (de) | 4'-epi-Daunomycuie, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen | |
| DE1811518C3 (de) | Daunonibicinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE2757102C2 (de) | Anthracyclinglycoside, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Mittel | |
| DE3508356C2 (en, 2012) | ||
| EP0286926B1 (de) | Semisynthetische Rhodomycine, Verfahren zu ihrer Herstellung und ihre Verwendung als Zytostatika | |
| DE2735455C3 (de) | Daunomycinanaloga, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE3028148A1 (de) | N-glykosylderivate der antibiotika aus der anthracylingruppe, verfahren zu deren herstellung und arzneimittel | |
| DE69029781T2 (de) | Anthracyclinglycosid-Derivate und Verfahren zu ihrer Herstellung | |
| DE2618009A1 (de) | 1-n-(alpha-hydroxy-omega-aminoacyl)-derivate des 3'-deoxykanamycins a und verfahren zur herstellung derselben | |
| DE2366288C3 (de) | Verfahren zur Herstellung von 3' -Desoxykanamycin B und 3' -Desoxyneamin | |
| DE2517293C2 (de) | Neue Cardenolid-&beta;-Glykoside, ihre Herstellung und Verwendung | |
| DE3317702C2 (en, 2012) | ||
| EP0277310A1 (de) | Zytostatisch wirksame Anthracyclinderivate | |
| CH660740A5 (de) | Halogenanthracyclinglykoside. | |
| DE2846383C3 (de) | l-(2-Chloräthyl)-l-nitroso-3-(D-ribofuranosyl)-harnstoffe, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2942818A1 (de) | Neue antitumoranthracycline mit einem gehalt an verzweigtkettigen aminodeoxyzuckern und verfahren zu deren herstellung | |
| DE3227178A1 (de) | 2'-modifizierte kanamycinderivate, verfahren zur herstellung derselben sowie mittel mit antibakterieller wirkung, die diese modifizierten kanamycinderivate enthalten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| C3 | Grant after two publication steps (3rd publication) |